Back to top

Image: Bigstock

Biotech Earnings Battle: Gilead (GILD) vs. Amgen (AMGN)

Read MoreHide Full Article

In this video, we take a look at two of the biggest and most important companies in the biotech space. Both are reporting earnings this week, and given the volatile nature of the sector lately, it will definitely be in investors’ best interest to see how two of the top dogs in this market fare in their quarterly reports.

After all, the space is likely to face some political risks with the upcoming election, while there are definitely valuation concerns. And given a top 30% industry rank, there are going to be plenty of stocks to buy in this space, but also a few to avoid too.

First, let’s take a quick look at Gilead Sciences (GILD - Free Report) , a California-based giant with a market cap over $100 billion. The stock currently has a Zacks Rank #2 (buy), while it has an ‘A’ Score for its VGM, so fundamentals are pretty impressive. However, it did just miss estimates to break its impressive streak, while growth rates aren’t that inspiring, making this a real mixed bag heading into earnings.

GILEAD SCIENCES Price, Consensus and EPS Surprise

GILEAD SCIENCES Price, Consensus and EPS Surprise | GILEAD SCIENCES Quote

Next up we have Amgen (AMGN - Free Report) , another large cap company which reports this week. The company is riding an impressive streak at earnings season which includes beats/meets in every quarter since early 2013. It is seeing solid growth projections, but it has been stuck in a narrow range in recent months. Add in a Zacks Rank #3 (hold) and a ‘B’ VGM score, and some of its fundamentals aren’t quite as good as GILD heading into the report.

AMGEN INC Price, Consensus and EPS Surprise

AMGEN INC Price, Consensus and EPS Surprise | AMGEN INC Quote

The biotech industry is promising overall and it currently has an Industry Rank in the top 30%, so either could be intriguing, though we discuss the better pick in the video. Make sure to watch for the selection, as well as more insights on both of these companies, including a more thorough discussion of their charts. And if you’d like more information on how to trade earnings reports, make sure to check out our podcast below:


See More Zacks Research for These Tickers


Normally $25 each - click below to receive one report FREE:


Amgen Inc. (AMGN) - free report >>

Gilead Sciences, Inc. (GILD) - free report >>